|
Crohn Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
IL-10 knockout (IL-10 KO) mice were used as the human CD models in this study.
|
31677991 |
2020 |
|
Crohn Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The interleukin-10 knockout (IL-10 KO) mouse is a well-known animal model of IBD that develops spontaneous intestinal inflammation resembling Crohns disease.
|
31158947 |
2020 |
|
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
These results suggest that IL-10 production by ManLAM-treated B cells contributes to keeping the balance between CD4<sup>+</sup> T cell subsets and protect mice from DSS-induced IBD.
|
31657484 |
2020 |
|
Inflammatory Bowel Diseases
|
0.700 |
GeneticVariation
|
group |
BEFREE |
The data suggest that endogenous T cell-derived opioids might reduce inflammation-induced abdominal pain in inflammatory bowel diseases associated with homozygous "loss of function mutations" in interleukin-10.
|
31588671 |
2020 |
|
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
The interleukin-10 knockout (IL-10 KO) mouse is a well-known animal model of IBD that develops spontaneous intestinal inflammation resembling Crohns disease.
|
31158947 |
2020 |
|
Inflammatory Bowel Diseases
|
0.700 |
GeneticVariation
|
group |
BEFREE |
SNPs rs1800896, rs3024505 (IL-10); rs11209026 (IL23R); rs2066844, rs2066845 (NOD-2), and rs2241880 (ATG16L1) were assessed in 93 patients with IBD and 200 healthy controls by hybridization probes and quantitative PCR.
|
31651650 |
2020 |
|
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
These results identify a regulatory interaction between IL-10 and PGE2, dysregulation of which may drive aberrant Mφ activation and impaired host defense contributing to IBD pathogenesis.
|
31819956 |
2020 |
|
Behcet Syndrome
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, a positive correlation was observed between IL-10 serum levels and ocular manifestations in BD patients, in contrast to those of IL-17, showing no correlation with the different clinical manifestations.
|
31122907 |
2019 |
|
Behcet Syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis showed that the IL-10 - 819 C/T and - 592 C/A polymorphisms are associated with BD susceptibility, especially in Asian population.
|
31721090 |
2019 |
|
Behcet Syndrome
|
0.700 |
Biomarker
|
disease |
BEFREE |
Treg and Th17 cell frequencies and Th17 RORγt expression were significantly elevated, and IL-10 concentration in Treg cell supernatants was significantly lower in BD patients than in controls.
|
30601931 |
2019 |
|
Behcet Syndrome
|
0.700 |
Biomarker
|
disease |
BEFREE |
HBV: hepatitis B virus; HCC hepatocellular carcinoma; TNFSF10: tumor necrosis factor superfamily member 10; ATG5: autophagy-related protein 5; DNA: deoxyribonucleic acid; LDR-PCR: ligase detection reactions-polymerase chain reaction; PCR: polymerase chain reaction; SLE: systemic lupus erythematosus; BD: Behçet's disease; IL-10: interlukin-10; LPS: lipopolysaccharide; PBMC: peripheral blood mononuclear cells; CWP: coal workers' pneumoconiosis; TNF-α: tumor necrosis factor-α.
|
30907204 |
2019 |
|
Crohn Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease.
|
30776076 |
2019 |
|
Crohn Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
One of the most common murine models for studying CD is IL-10-/- mouse.
|
31509557 |
2019 |
|
Crohn Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In addition, the levels of IgG x TNF, IgA x IL-10 and IgG x IL-10 were also correlated in CD, indicating that ASCA production may be influenced by the inflammatory response.
|
30884988 |
2019 |
|
Crohn Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Furthermore, in CD, circRNA_103516 correlated positively with CDAI (<i>P</i> < 0.001), CRP (<i>P</i> < 0.001), ESR (<i>P</i> < 0.001), TNF-α (<i>P</i> < 0.001), and IFN-γ (<i>P</i> < 0.001) and negatively correlated with IL-10 (<i>P</i> = 0.006).
|
31749597 |
2019 |
|
Crohn Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Additionally, lncRNA ANRIL expression was negatively associated with Crohn's disease activity index (P = 0.002), C-reactive protein (P < 0.001) and erythrocyte sedimentation rate (P = 0.001), and associated with tumor necrosis factor-α (P < 0.001), IL-17 (P < 0.001) and interferon gamma messenger RNA levels (P = 0.004) but positively associated with IL-10 messenger RNA level (P = 0.002).
|
30665494 |
2019 |
|
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
Here, we show that in a murine inflammatory bowel disease (IBD) model based on macrophage-restricted interleukin-10 (IL-10) receptor deficiency (<i>Cx3cr1<sup>Cre</sup>:Il10ra<sup>fl/fl</sup></i> mice), proinflammatory mutant gut macrophages cause severe spontaneous colitis resembling the condition observed in children carrying IL-10R mutations.
|
31201258 |
2019 |
|
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
However, little is known regarding the role of PI3Kδ on IL-10-producing B cells that help regulate mucosal inflammation in IBD.
|
31546615 |
2019 |
|
Inflammatory Bowel Diseases
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Consistent with the PBMC data, both <i>L. fermentum</i> KBL374- and KBL375-treated DSS mice demonstrated decreased Th1-, Th2-, and Th17-related cytokine levels and increased IL-10 in the colon compared with the DSS control mice.Administration of <i>L. fermentum</i> KBL374 or KBL375 to mice increased the CD4+CD25+Foxp3+Treg cell population in mesenteric lymph nodes.Additionally, <i>L. fermentum</i> KBL374 or KBL375 administration reshaped and increased the diversity of the gut microbiota.In particular, <i>L. fermentum</i> KBL375 increased the abundance of beneficial microorganisms, such as <i>Lactobacillus</i> spp. and <i>Akkermansia</i> spp.Both <i>L. fermentum</i> KBL374 and KBL375 may alleviate inflammatory diseases, such as inflammatory bowel disease, in the gut by regulating immune responses and altering the composition of gut microbiota.
|
30939976 |
2019 |
|
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
Loss of IL-10 promotes the development of inflammatory bowel disease (IBD) as a consequence of an excessive immune response to the gut microbiota.
|
31727465 |
2019 |
|
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
Ascl2 facilitates IL-10 production in Th17 cells to restrain their pathogenicity in inflammatory bowel disease.
|
30722992 |
2019 |
|
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
We observed that C3H ASF and 129 ASF IL-10 are more sensitive towardB7 600 μg/mL vitamin B<sub>3</sub> and 1,200 μg/mL vitamin C. The lowest growth rate and viability for all types of organoids was with 1,200 μg/mL vitamin C. From quantitative polymerase chain reaction analysis (qPCR analysis), MUC2 was upregulated for 129 ASF and C3H Conv when exposed to 600 μg/mL and 1,200 μg/mL vitamin C. It suggests that large amounts of glycoprotein may be produced after adding high concentrations of vitamin C. Since inflammatory bowel disease has low level of MUC2, this finding may be helpful in restoring mucosal health by upregulating the MUC2 gene while altering patient's microbiota (Sibila et al., Annals of the American Thoracic Society, 2016).
|
31071241 |
2019 |
|
Inflammatory Bowel Diseases
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Mutations in interleukin-10 and its receptors cause infantile inflammatory bowel disease (IBD), a hyperinflammatory disorder characterized by severe, treatment-refractory colitis, multiple abscesses, and enterocutaneous fistulas.
|
29683948 |
2019 |
|
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
IL10 is an anti-inflammatory cytokine, so Tr1 cells might be used in the treatment of inflammatory bowel diseases.
|
31513797 |
2019 |
|
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
We investigated two main types of Tregs, the CD4+FOXP3+ and IL-10+ Tr1, in pediatric subjects with inflammatory bowel disease (IBD) both at diagnosis and after the clinical remission.
|
31715619 |
2019 |